Results 91 to 100 of about 1,090 (148)
Some of the next articles are maybe not open access.
Journal of the American Academy of Dermatology, 1989
Cyclosporine is a potent immunosuppressive agent with no appreciable effect on the bone marrow and a selective inhibitory effect on helper T cells. Oral cyclosporine was first used to prevent organ rejection but also has been reported to be effective in other disorders. In cutaneous diseases that respond to oral cyclosporine helper T cells appear to be
A K, Gupta +7 more
openaire +2 more sources
Cyclosporine is a potent immunosuppressive agent with no appreciable effect on the bone marrow and a selective inhibitory effect on helper T cells. Oral cyclosporine was first used to prevent organ rejection but also has been reported to be effective in other disorders. In cutaneous diseases that respond to oral cyclosporine helper T cells appear to be
A K, Gupta +7 more
openaire +2 more sources
Cyclosporine immunosuppression
American Journal of Health-System Pharmacy, 1984The chemistry, pharmacokinetics, mechanism of action, clinical efficacy in organ transplants, adverse effects, and dosage and administration of cyclosporine, a new immunosuppressant, are reviewed. Advice on counseling patients who take the drug is also included. Cyclosporine is a cyclic undecapeptide with a high molecular weight.
D M, Canafax, N L, Ascher
openaire +2 more sources
Annals of Internal Medicine, 1987
Excerpt To the editor: Graves disease with ophthalmopathy was diagnosed in a 37-year-old woman. Treatment consisted of propranolol, 20 mg three times a day, propylthiouracil, 100 mg three times a d...
Noppen, Marc +4 more
openaire +2 more sources
Excerpt To the editor: Graves disease with ophthalmopathy was diagnosed in a 37-year-old woman. Treatment consisted of propranolol, 20 mg three times a day, propylthiouracil, 100 mg three times a d...
Noppen, Marc +4 more
openaire +2 more sources
Transplantation Proceedings, 2004
The concentration at 2 hours after drug intake (C2) is proposed to optimise clinical outcomes in organ transplantation and for adjustment of the regimen of cyclosporine. A population based pharmacokinetic study was undertaken during the first 30 days post-liver transplantation.
M, Billing-Grima, P, Wolf
openaire +4 more sources
The concentration at 2 hours after drug intake (C2) is proposed to optimise clinical outcomes in organ transplantation and for adjustment of the regimen of cyclosporine. A population based pharmacokinetic study was undertaken during the first 30 days post-liver transplantation.
M, Billing-Grima, P, Wolf
openaire +4 more sources
Transplantation Proceedings, 2004
The introduction of cyclosporine (CSA) into organ transplantation was a landmark achievement leading to a substantial improvement of the early transplant results. It was particularly the reduction in early severe acute rejections that accounted for this improvement.
J M, Grinyó, J M, Cruzado
openaire +4 more sources
The introduction of cyclosporine (CSA) into organ transplantation was a landmark achievement leading to a substantial improvement of the early transplant results. It was particularly the reduction in early severe acute rejections that accounted for this improvement.
J M, Grinyó, J M, Cruzado
openaire +4 more sources
Folia Microbiologica, 1995
This review presents the progress and some aspects achieved during recent years with cyclosporin sources, chemistry, biological activities, side effects, biosynthesis and metabolism. Although incomplete the results indicate future research trends and some white spots to be studied in the near future to afford unique insights into cell biology and to ...
openaire +2 more sources
This review presents the progress and some aspects achieved during recent years with cyclosporin sources, chemistry, biological activities, side effects, biosynthesis and metabolism. Although incomplete the results indicate future research trends and some white spots to be studied in the near future to afford unique insights into cell biology and to ...
openaire +2 more sources
Clinics in Dermatology, 1991
Abstract Cyclosporine A (CyA) is a potent immunosuppressive agent with a selective and reversible inhibitory effect on T-cell functions, especially interleukin-2 production. The drug is not myelotoxic, mutagenic, or teratogenic and is extremely effective in preventing rejection of grafted organs.
openaire +2 more sources
Abstract Cyclosporine A (CyA) is a potent immunosuppressive agent with a selective and reversible inhibitory effect on T-cell functions, especially interleukin-2 production. The drug is not myelotoxic, mutagenic, or teratogenic and is extremely effective in preventing rejection of grafted organs.
openaire +2 more sources
Drug Intelligence & Clinical Pharmacy, 1986
Cyclosporine is an important immunosuppressive agent in organ and bone marrow transplantation. The pharmacokinetics of cyclosporine are quite complex and are complicated by the availability of two assay systems that yield differing results. This article summarizes the views from two major solid organ transplant centers and one bone marrow transplant ...
G J, Burckart, D M, Canafax, G C, Yee
openaire +2 more sources
Cyclosporine is an important immunosuppressive agent in organ and bone marrow transplantation. The pharmacokinetics of cyclosporine are quite complex and are complicated by the availability of two assay systems that yield differing results. This article summarizes the views from two major solid organ transplant centers and one bone marrow transplant ...
G J, Burckart, D M, Canafax, G C, Yee
openaire +2 more sources
Cyclosporine and Prostaglandins
Annals of Internal Medicine, 1985Excerpt To the editor: Cyclosporine and its nephrotoxicity have recently been reviewed in your journal (1). Subsequently, Dr.
D, Adu +4 more
openaire +2 more sources
Clinics in Laboratory Medicine, 1987
Cyclosporine is a potent immunosuppressant with low myelotoxicity. It is approved for use to prevent rejection of kidney, liver, and heart transplants, and is being investigated for possible use for suppression of graft-versus-host disease in patients who have received bone marrow transplants.
openaire +2 more sources
Cyclosporine is a potent immunosuppressant with low myelotoxicity. It is approved for use to prevent rejection of kidney, liver, and heart transplants, and is being investigated for possible use for suppression of graft-versus-host disease in patients who have received bone marrow transplants.
openaire +2 more sources

